Wuhan, China — Wuhan QR Science and Technology Development Co., Ltd. (“QR Science and Technology”) today announced a landmark donation of RMB 100 million (approximately USD 14 million) to Huazhong University of Science and Technology (HUST) in support of medical education and scientific research advancement at the university.

Donation Ceremony

The donation signing ceremony between QR Science and Technology and the HUST Education Development Foundation was held on March 13 at HUST. Distinguished attendees included You Zheng, President of HUST; Zhang Yonghui, Vice President of HUST and Party Secretary of Tongji Medical College; Academician Ma Ding; Academician Wu Tangchun, Dean of Tongji Medical College; and Wang Chaodong, Chairman of QR Science and Technology, along with other senior executives from the group.

At the ceremony, Dai Zejian, Secretary-General of the Education Development Foundation, signed the donation agreement with Hu Yuan, Deputy General Manager of QR Science and Technology. Yang Guoping, Deputy General Manager of Createrna, presented the donation check to Huang Rui, Party Secretary of the School of Pharmacy. President You Zheng presented a commemorative donation plaque to alumnus Wang Chaodong.

Chairman's Vision

During the ceremony, Chairman Wang Chaodong reflected on his formative experiences at the university. He emphasized that Tongji Medical College's educational traditions—particularly its emphasis on integrating basic and clinical medicine across disciplines, together with its rigorous academic culture—laid a solid foundation for his career in the pharmaceutical industry and for the company's current focus on innovative drug research and development.

Chairman Wang expressed his aspiration that, through establishing an Early Clinical Research Center at Tongji Medical College, the donation would support the university's advancement in medicine and pharmaceutical sciences under the new paradigm of medical-engineering integration. He further stated that this initiative would help the company better navigate the “valley of death” in new drug development—the critical transition from preclinical stages to early clinical phases—and leverage artificial intelligence to generate more impactful outcomes, address unmet health challenges, and contribute meaningfully to global medical advancement and drug discovery.